$Esperion Therapeutics (ESPR.US)$ Deception is the patent of the spiritual world, and the level of deception in human hearts is top-notch. If you do not focus on the value of stocks in your investment, you will perish from the deceitful heart, including Institutions investors, the breath of Lehman Brothers' death is summoning the deceitful heart!

$Organon & Co (OGN.US)$
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global health...

$Esperion Therapeutics (ESPR.US)$ Looking at the number of employees in the company, it does not have its own sales channel and team, but there is no need to doubt the company's academic promotion capabilities. The global agent sales model adopted by the company is an effective strategy for low-cost expansion, and the partners are all strong.

$Esperion Therapeutics (ESPR.US)$ When a stock is undervalued, shorting is not a wise choice.

$Esperion Therapeutics (ESPR.US)$ According to the 30-day moving average line of the monthly candlestick, the target for December is $3.17.

$Organon & Co (OGN.US)$ Non-steroidal treatment for skin diseases, especially difficult-to-treat Silver syndrome, is unique and bullish on future earnings.

$Esperion Therapeutics (ESPR.US)$ First: With increasing evidence of the relationship between statins and Alzheimer's disease, the sales of this drug will see a significant growth. Second: Even if it fills the market for statin intolerance, it is enough to support a stock price of 6-8 dollars.

$Esperion Therapeutics (ESPR.US)$ Figstime Theorem: The higher the proportion of speculative behavior in investment, the lower the rate of return on investment. Based on my 30 years of observation in the pharmaceutical industry, once pharmaceutical companies pass product evaluations, their income and profits show steady growth, making investment in the pharmaceutical industry conservative. This is my view on this stock.

$Esperion Therapeutics (ESPR.US)$ If it can reclaim the 20-day moving average today, it could return to $3 by the end of December.

$Esperion Therapeutics (ESPR.US)$ Near the 2.40 price level, there is support. The turnover ratio has increased in the short term, and after the panic sentiment on the market surface erupts, the symptoms have slightly improved.